Patents by Inventor Knut Adermann

Knut Adermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140024585
    Abstract: A composition containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP.
    Type: Application
    Filed: April 11, 2011
    Publication date: January 23, 2014
    Inventors: Wolf Georg Forssmann, Rudolf Richter, Knut Adermann, Markus Meyer
  • Patent number: 8299031
    Abstract: Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: October 30, 2012
    Assignee: Viro Pharmaceuticals GmbH & Co. KG
    Inventors: Ludger Ständker, Wolf-Georg Forssmann, Knut Adermann, Jan Münch, Frank Kirchhoff, Elke Rücker
  • Publication number: 20100317600
    Abstract: The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary electrophoresis, as well as to appropriate processes for the preparation of same.
    Type: Application
    Filed: February 9, 2010
    Publication date: December 16, 2010
    Inventors: Hansueli Immer, Wolf-Georg Forssmann, Knut Adermann, Christian Klessen
  • Patent number: 7655629
    Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X13 is an amino acid with a hydrophobic or an aromatic side chain; X14 is a
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: February 2, 2010
    Assignee: IPF Pharmaceuticals GmbH
    Inventors: Knut Adermann, Frank Kirchhoff, Jan Münch, Axel Schulz
  • Publication number: 20090240031
    Abstract: The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary electrophoresis, as well as to appropriate processes for the preparation of same.
    Type: Application
    Filed: July 27, 2007
    Publication date: September 24, 2009
    Applicant: Pharis Biotec GmbH
    Inventors: Hansueli Immer, Wolf-Georg Forssmann, Knut Adermann, Christian Klessen
  • Publication number: 20090191206
    Abstract: Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.
    Type: Application
    Filed: January 25, 2007
    Publication date: July 30, 2009
    Applicant: VIRO PHARMACEUTICALS GMBH & CO. KG
    Inventors: Ludger Ständker, Wolf-Georg Forssmann, Knut Adermann, Jan Münch, Frank Kirchhoff, Elke Rücker
  • Publication number: 20090149391
    Abstract: The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 11, 2009
    Inventors: Cornelia Liepke, Susann Baxmann, Knut Adermann
  • Publication number: 20090124541
    Abstract: The invention relates to the novel peptides, derived from human blood, hBD-5 (human beta-defensin-5), hBD-6, hBD-7, hBD-8, hBD-10, hBD-11, hBD-12, hBD-13, hBD-14, hBD-15, hBD-16, hBD-17, hBD-18, hBD-19, hBD-20, hBD-22, hBD-23, hBD-24, hBD-25, hBD-26, hBD-27, hBD-28, hBD-29, hBD-30, hBD-31 and hBD-32 and their derivatives whose structure was elucidated for the purpose of therapeutic, diagnostic and commercial use as medicaments. The peptides can be prepared by biotechnological, recombinant methods, by chemical synthesis as well as by proteolysis from corresponding precursor proteins.
    Type: Application
    Filed: April 27, 2007
    Publication date: May 14, 2009
    Inventors: Wolf-Georg Forssmann, Knut Adermann, Jose-Ramon Conejo-Garcia
  • Patent number: 7449545
    Abstract: The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: November 11, 2008
    Assignee: IPF Pharmaceuticals GmbH
    Inventors: Cornelia Liepke, Susann Baxmann, Knut Adermann
  • Publication number: 20080242609
    Abstract: A composition containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP.
    Type: Application
    Filed: October 15, 2007
    Publication date: October 2, 2008
    Inventors: Wolf Georg Forssmann, Rudolf Richter, Knut Adermann, Markus Meyer
  • Publication number: 20070123465
    Abstract: The invention relates to oligomeric peptides with biological activity against HIV infection having the amino acid sequence (Z1-LE-X1-IP—X2—X3—X4—P—X5—X6—X7—X8—X9—X10—K—X11—X12—X13—X14—X15-Z2)n, wherein n indicates the number of monomeric peptide chains, whereby n is 2, 3 or 4; X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahyd
    Type: Application
    Filed: June 17, 2005
    Publication date: May 31, 2007
    Applicant: IPF PHARMACEUTICALS GMBH
    Inventors: Knut Adermann, Frank Kirchhoff, Jan Munch, Axel Schulz, Wolf-Georg Forssmann
  • Publication number: 20060252915
    Abstract: The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
    Type: Application
    Filed: December 4, 2002
    Publication date: November 9, 2006
    Inventors: Cornelia Liepke, Susann Baxmann, Knut Baxmann, Knut Adermann
  • Publication number: 20060122371
    Abstract: The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary electrophoresis, as well as to appropriate processes for the preparation of same.
    Type: Application
    Filed: March 21, 2005
    Publication date: June 8, 2006
    Inventors: Hansueli Immer, Wolf-Georg Forssmann, Knut Adermann, Christian Klessen
  • Publication number: 20050130891
    Abstract: A composition containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP.
    Type: Application
    Filed: May 13, 2004
    Publication date: June 16, 2005
    Inventors: Wolf Forssmann, Rudolf Richter, Knut Adermann, Markus Meyer
  • Publication number: 20040116652
    Abstract: The invention relates to the novel peptides, derived from human blood, hBD-5 (human beta-defensin-5), hBD-6, hBD-7, hBD-8, hBD-10, hBD-11, hBD-12, hBD-13, hBD-14, hBD-15, hBD-16, hBD-17, hBD-18, hBD-19, hBD-20, hBD-22, hBD-23, hBD-24, hBD-25, hBD-26, hBD-27, hBD-28, hBD-29, hBD-30, hBD-31 and hBD-32 and their derivatives whose structure was elucidated for the purpose of therapeutic, diagnostic and commercial use as medicaments. The peptides can be prepared by biotechnological, recombinant methods, by chemical synthesis as well as by proteolysis from corresponding precursor proteins.
    Type: Application
    Filed: January 13, 2003
    Publication date: June 17, 2004
    Inventors: Wolf-Georg Forssmann, Knut Adermann, Jose-Ramon Conejo-Garcia
  • Publication number: 20030186889
    Abstract: The present invention relates to the provision of a medicament and of a diagnostic agent obtained by proteome analysis, preferably containing at least two different chemokine receptor ligands or chemokine receptor antibodies, and further to the use of at least two different chemokine receptor ligands, chemokine receptor antibodies and/or two different chemokine receptors. As inhibitors, the medicament preferably contains ligands or antibodies of at least two chemokine receptors or the related algorithms of the surface chemokine receptor proteome, and the use of at least one chemokine receptor ligand and/or chemokine receptor, peptides and antibodies and their use for the diagnostics and therapy of tumor diseases and inflammatory diseases. By way of analogy, clusters of analyzed tumor cell surface proteomes, such as ectoproteases, adhesion molecules or various receptor types, can also be used.
    Type: Application
    Filed: September 23, 2002
    Publication date: October 2, 2003
    Inventors: Wolf-Georg Forssmann, Ulf Forssmann, Knut Adermann, Aleksandra Heitland, Nicolaj Spodsberg
  • Publication number: 20030171536
    Abstract: The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary electrophoresis, as well as to appropriate processes for the preparation of same.
    Type: Application
    Filed: February 23, 1998
    Publication date: September 11, 2003
    Inventors: HANSUELI IMMER, WOLF-GEORG FORSSMANN, KNUT ADERMANN, CHRISTIAN KLESSEN
  • Patent number: 6579849
    Abstract: A peptide having the amino acid sequence H2N—X1—R—X3—X2—COOH  (formula I) wherein X1 is either zero or X1 and/or X2 are a residue representing at least five amino acid residues (symbolized in the one letter amino acid code), preferably naturally occurring amino acids, with the proviso that X1 and/or X2 contain at least one basic amino acid residue immediately followed by a hydrophobic amino acid residue and X1 and/or X2 contain at least one glutamine residue.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: June 17, 2003
    Assignee: HaemoPep Pharma GmbH
    Inventors: Wolf-Georg Forssmann, Hans-Dieter Zucht, Manfred Raida, Knut Adermann, Hans-Jürgen Mägert
  • Publication number: 20020025928
    Abstract: A peptide having the amino acid sequence
    Type: Application
    Filed: September 24, 1998
    Publication date: February 28, 2002
    Inventors: WOLF-GEORG FORSSMANN, HANS-DIETER ZUCHT, MANFRED RAIDA, KNUT ADERMANN, HANS-JURGEN MAGERT
  • Patent number: 6030790
    Abstract: The present invention is directed to peptides from the sequence of hPTH(1-37), which contain .alpha.-helical amino acid sequence regions and/or non-structured amino acid sequence regions, said peptides being capable of inducing antibodies when injected into animals. Furthermore, the invention is directed to a diagnostic agent and antibodies obtainable by immunizing animals using the peptides according to the invention.
    Type: Grant
    Filed: March 27, 1997
    Date of Patent: February 29, 2000
    Assignee: Haemopep Pharma GmbH
    Inventors: Knut Adermann, Dieter Hock, Markus Magerlein